Literature DB >> 30175752

Isolation of Escherichia coli carrying the blaCTX-M-1 and qnrS1 genes from reproductive organs of broiler breeders and internal contents of hatching eggs.

Qada Benameur1,2, Hassiba Tali-Maamar3, Farida Assaous3, Badia Guettou3, Naϊma Tahrat3, Nadjet Aggoune4, Kheira Rahal3, Meriem-Hind Ben-Mahdi2,5.   

Abstract

This study aimed to characterize two third-generation cephalosporins- and quinolone-resistant Escherichia coli (TGCs- and Q-R-Ec) isolates recovered from the ovaries of a broiler breeder flock and the internal contents of hatching eggs produced by the broiler breeder flock. Clonal relatedness was determined by multilocus sequence typing (MLST). The isolates displayed the same multidrug resistance profile, with resistance to ampicillin, ticarcillin, piperacillin, cefazollin, cephalothin, cefotaxime, nalidixic acid, tetracycline and sulfonamides. Double disk synergy test demonstrated that the two isolates presented an ESBL phenotype. PCR and sequencing results showed that both the isolates harbored the blaCTX-M-1 and qnrS1 genes. MLST revealed a novel allele combination, designated as ST461, in these isolates. This study would contribute to the molecular epidemiological understanding of TGCs- and/or Q-R-Ec.

Entities:  

Keywords:  PCR; antimicrobial resistance; molecular epidemiology; ovary; poultry

Mesh:

Substances:

Year:  2018        PMID: 30175752      PMCID: PMC6207526          DOI: 10.1292/jvms.18-0283

Source DB:  PubMed          Journal:  J Vet Med Sci        ISSN: 0916-7250            Impact factor:   1.267


The increasing trend of third-generation cephalosporins- and quinolone-resistant Escherichia coli (TGCs- and Q-R-Ec) in food-producing animals worldwide is worrisome [19, 22], due to the significance of TGCs and quinolones in human and veterinary medicine. The production of extended-spectrum β-lactamases (ESBLs) is the most encountered mechanism responsible for resistance to TGCs. TEM, SHV, and CTX-M-types are the three major families of ESBL [6]. CTX-M is the most extended group among ESBL enzymes, and due to its increasing prevalence (higher than TEM and SHV), some authors have announced the “CTX-M ESBL pandemic” [7]. Plasmid-mediated quinolone resistance (PMQR) determinants qnr gene has been subsequently reported [24]. In most cases, strains also had ESBLs, which raises the risk for transfer of multidrug resistant E. coli to humans [26]. Recently, TGCs- and/or Q-R-Ec isolates have been isolated at all levels of the broiler production pyramid, including chicken meat, in several countries [4, 7, 20, 21]. It has also been detected at commercial hatcheries, in one day old broiler chicks that had not been treated with antimicrobial before [10, 27], suggesting that particular TGCs- and/or Q-R-Ec clones are introduced through import of breeder stock and hatching eggs and disseminated via vertical transmission through the broiler production pyramid. Several experimental investigations have been employed to demonstrate possible colonization of hatching eggs by antimicrobial resistant (AMR) E. coli [8, 18]. Until now, there is no indication that trans-ovarian transmission plays a role in the dissemination of TGCs- and/or Q-R-Ec. To the author’s knowledge, studies on vertical transmission of AMR E. coli from parent birds to their offspring have not been carried out so far since these bacteria have not been isolated from the reproductive organs of parent birds and/or internal contents of hatching eggs. The aim of this study was to characterize two TGCs- and Q-R-Ec strains isolated from the ovaries of a broiler breeder flock and the internal contents of hatching eggs produced by the broiler breeder flock. Two ESBL-producing Escherichia coli strains (E. coli S1 and E. coli S2) were included in this study. The first strain (E. coli S1) was isolated from a pooled sample of the ovaries of broiler breeders collected from a breeder flock situated in Chlef province, Western Algeria, and the second one (E. coli S2) was recovered from a sample of internal contents of broiler hatching eggs collected from a commercial broiler hatchery located in Mostaganem province, North-western Algeria. Eggs produced by the breeder flock in Chlef province were transported to the hatchery in Mostaganem province. Hatching eggs were collected one week after the sampling of the ovaries. The samples were collected following the instructions of veterinarians in those facilities and submitted to the Regional Veterinary Laboratory of Mostaganem, Algeria, for routine antimicrobial resistance monitoring. According to the veterinarian, a drop in egg production (12.53%) was observed in the breeder flock sampled. The samples were processed immediately upon arrival using aseptic techniques. Ten birds, randomly sampled from the breeder flock, were necropsied in the laboratory and only the ovaries were collected. The ovaries were pooled in a sterile tube and were then flamed for 5 sec using a Bunsen burner, for disinfecting their surface, and cut into small dice. Visually clean hatching eggs (20 eggs) were also randomly collected in sterile plastic bags and transported to the laboratory on ice in an ice box. After disinfection of the surface of the eggshell, by dipping the eggs into 2% tincture iodine for 1 min, the egg internal contents were examined as described previously [8]. One ml or g of the samples (egg internal contents or ovaries) was mixed with 9 ml of buffered peptone water, vortexed and incubated at 37°C overnight. To isolate E. coli, a drop of broth was streaked on MacConkey’s agar. Isolates were further identified using the API 20E System (BioMérieux, Marcy l’Etoile, France). Antimicrobial susceptibility tests of the E. coli isolates were carried out using the disk diffusion method and minimal inhibitory concentrations (MICs) following Clinical and Laboratory Standards Institute guidelines [9]. The isolates were tested against a panel of 23 antimicrobials including many that are important to both human and veterinary medicine: nalidixic acid (30 µg), flumequin (30 µg), ciprofloxacin (5 µg), levofloxacin (5 µg), ampicillin (10 µg), amoxicillin-clavulanic acid (20/10 µg), ticarcillin (75 µg), piperacillin (100 µg), cefazollin (30 µg), cephalothin (30 µg), ceftazidime (30 µg), cefotaxime (30 µg), aztreonam (30 µg), cefepime (30 µg), cefriaxone (30 µg), tetracycline (30 µg), sulfonamides (300 µg), trimethoprim (5 µg), trimethoprim-sulfamethoxazole (1.25/23.75 µg), imipenem (10 µg), gentamicin (10 µg), chloramphenicol (30 µg), and nitrofurantoin (300 µg) (Bio-Rad, Marnes-la-Coquette, France). The MICs against cefotaxime, ceftazidime, aztreonam, cefepime, cefriaxone, nalidixic acid, ciprofloxacin and levofloxacin were determined using E-test (AES, AB Biodisk, Solna, Sweden). The MIC value for colistin was determined by broth microdilution method following EUCAST recommendations [25]. E. coli ATCC 25922 (American Type Culture Collection, Rockville, MD, U.S.A.) was used as a quality control strain. Double disk synergy test (DDST) was performed to confirm ESBL production as described by Jarlier et al. [15] using a central amoxicillin/clavulanic acid disk, 30 mm away from cefotaxim, ceftriaxone, ceftazidim, and aztreonam disks. The presence of ESBL was revealed by a champagne cork aspect. The E. coli isolates were also subjected to PCR for the detection of blaESBL as described previously for blaCTX-M genotype groups 1, 2, 8 and 9 [1], blaSHV [1], and blaTEM [17]. The isolates were also screened for qnr-type genes (qnrA, qnrB and qnrS) as previously described [11, 12, 14]. PCR amplicons were confirmed by sequencing and the DNA sequences obtained were compared with those in the GenBank using the BLAST program. To analyze the possible clonal relatedness between the E. coli isolates, molecular typing by multilocus sequence typing (MLST) was used. Internal fragments of eight housekeeping genes (dinB, icdA, pabB, polB, putP, trpA, trpB and uidA) were studied by PCR and sequencing according to the method of Jaureguy et al. [16] Allele sequences and sequence typing were assigned according to Institute Pasteur’s MLST scheme for E. coli. Congestion and swelling of the ovaries were observed on post mortem examination in 3 out of the 10 ovaries examined. E. coli was isolated in pure culture on MacConkey’s agar from the two specimens. The two isolates displayed the same antimicrobial resistance profile, with resistance to ampicillin, ticarcillin, piperacillin, cefazollin, cephalothin and cefotaxime. Both isolates were susceptible to ceftazidime and imipenem. The MIC values indicated that these isolates showed reduced susceptibility to cefepime and aztreonam (Table 1). On another hand, the isolates were resistant to nalidixic acid, tetracycline and sulfonamides, but susceptible to ciprofloxacin, trimethoprim-sulfamethoxazole, chloramphenicol, nitrofurantoin and colistin. DDST demonstrated that both isolates presented an ESBL phenotype. In addition, PCR screening for blaESBL and qnr genes showed that the two isolates coproduced blaCTX-M- and qnrS-encoding genes. According to sequencing results, the blaCTX-M and qnr genes harbored by the two isolates were blaCTX-M-1 and qnrS1. By MLST, a novel allele combination (25-47-10-10-16-57-4-50) was found in both the isolates and is designated as ST461.
Table 1.

Characteristics of E. coli isolates

IsolateSpecimenResistance profileMICs (µg/ml)bla geneQnr determinantSequence type

CTXCAZFEPATMCRONACIPLEVCT
E. coli S1Broiler breedersAM, TIC, PIP, CZ, CF, CTX, NA, TE, SSS>32312664>2560.250.50.125CTX-M-1qnrS1ST461
E. coli S2Hatching eggsAM, TIC, PIP, CZ, CF, CTX, NA, TE, SSS>323126128 >2560.380.750.125CTX-M-1qnrS1ST461

MIC, minimum inhibitory concentration; AM, ampicillin; TIC, ticarcillin; PIP, piperacillin; CZ, cefazollin; CF, cephalothin; CTX, cefotaxime; CAZ, ceftazidime; FEP: cefepime; ATM, aztreonam; CRO, cefriaxone; NA, nalidixic acid; CIP, ciprofloxacin; LVX, levofloxacin; TE, tetracycline; SSS, sulfonamides; CT, colistin.

MIC, minimum inhibitory concentration; AM, ampicillin; TIC, ticarcillin; PIP, piperacillin; CZ, cefazollin; CF, cephalothin; CTX, cefotaxime; CAZ, ceftazidime; FEP: cefepime; ATM, aztreonam; CRO, cefriaxone; NA, nalidixic acid; CIP, ciprofloxacin; LVX, levofloxacin; TE, tetracycline; SSS, sulfonamides; CT, colistin. In recent years, there has been increasing concern in the scientific community about the emergence and dissemination of TGCs- and Q-R-Ec within the broiler production pyramid [4, 5, 20]. Import of breeding animals has been suggested as the most likely source for introduction of antimicrobial resistance to the broiler production [10, 20]. In this study, E. coli isolates harboring the blaCTX-M-1 and qnrS1 genes belonging to ST461 were detected in the ovaries of a broiler breeder flock and subsequently in the internal contents of hatching eggs originating from the broiler breeder flock. The presence of E. coli in egg internal contents may be due to penetration through the eggshell during or after oviposition as previously demonstrated [8]. A recent study has reported the presence of TEM- and SHV-producing Enterobacteriaceae isolates in the shell surface and shell crushed of broiler hatching eggs [18]. Another explanation is by direct contamination before oviposition, originating from the infection of reproductive organs with E. coli. Isolation of E. coli harboring the blaCTX-M-1 and qnrS1 genes from the ovaries of the broiler breeders in this study strongly suggests the latter hypothesis which may be responsible for ovaritis and associated with reduced egg production. Indeed, TGCs-R-Ec has also been detected, in commercial hatcheries, in one-day-old chicks that had not been treated with antimicrobial before [10]. In Algeria, a few investigations have demonstrated the presence of qnr determinants in isolates from animals and food of animal origin. Among them, qnrA has been recently identified in SHV-12-producing E. coli isolates from poultry [2], and qnrS1 and qnrB5 in ESBL-producing E. coli isolates from companion animals [28]. In this study qnrS1 was reported in CTX-M-1 producing E. coli. Recently, qnrS1 has also been detected in non-ESBL-producing E. coli and Enterobacter cloacae of poultry origin [3]. The results of this study revealed that the isolates showed a high level of resistance to nalidixic acid (MIC>256), but they remained susceptible to ciprofloxacin and levofloxacin. Generally, the plasmid-mediated mechanisms provide only low-level resistance that by itself does not exceed the clinical breakpoint for susceptibility [13]. MICs of nalidixic acid in the isolates from ovary and egg content samples may be due to a mutation(s) in the quinolone resistance-determining regions including gyrA and parC genes. Resistance to other antibiotics was also observed in the two E. coli isolates. It has been reported that the prevalence of co-resistance to nalidixic acid and sulfonamides was high among ESBL-producing E. coli [2]. This can be explained by the ESBL-plasmids often carry other genes of resistance (particularly to aminosides, tetracyclins and sulfamides) suggesting co-resistance, co-expression, and co-selection as previously reported [23]. In conclusion, this is the first report demonstrating the presence of TGCs- and Q-R-Ec in the reproductive organs of broiler breeders and internal contents of hatching eggs. The present results would contribute to the molecular epidemiological understanding of TGCs- and Q-R-Ec. However, further molecular epidemiological studies are needed in order to characterize a large number of AMR isolates.
  25 in total

Review 1.  The CTX-M beta-lactamase pandemic.

Authors:  Rafael Cantón; Teresa M Coque
Journal:  Curr Opin Microbiol       Date:  2006-08-30       Impact factor: 7.934

Review 2.  The CTX-M conundrum: dissemination of plasmids and Escherichia coli clones.

Authors:  Umaer Naseer; Arnfinn Sundsfjord
Journal:  Microb Drug Resist       Date:  2011-01-31       Impact factor: 3.431

3.  A nosocomial outbreak of Escherichia coli producing CTX-M-15 and OXA-30 beta-lactamase.

Authors:  Hyunjoo Pai; Mi Ran Kim; Mi-Ran Seo; Tae Yeal Choi; Sung Hee Oh
Journal:  Infect Control Hosp Epidemiol       Date:  2006-03-01       Impact factor: 3.254

4.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.

Authors:  V Jarlier; M H Nicolas; G Fournier; A Philippon
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

5.  Prevalence of ESBLs and PMQR genes in fecal Escherichia coli isolated from the non-human primates in six zoos in China.

Authors:  Yang Wang; Tao He; Jing Han; Juan Wang; Steven L Foley; Guangyou Yang; Shuangxiu Wan; Jianzhong Shen; Congming Wu
Journal:  Vet Microbiol       Date:  2012-03-13       Impact factor: 3.293

6.  Prevalence of plasmid-mediated quinolone resistance.

Authors:  George A Jacoby; Nancy Chow; Ken B Waites
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

7.  Introduction of quinolone resistant Escherichia coli to Swedish broiler population by imported breeding animals.

Authors:  Stefan Börjesson; Thomas Guillard; Annica Landén; Björn Bengtsson; Oskar Nilsson
Journal:  Vet Microbiol       Date:  2015-11-12       Impact factor: 3.293

8.  Characterization of quinolone-resistant Enterobacteriaceae strains isolated from poultry in Western Algeria: First report of qnrS in an Enterobacter cloacae.

Authors:  Qada Benameur; Hassiba Tali-Maamar; Farida Assaous; Badia Guettou; Meki Boutaiba Benklaouz; Kheira Rahal; Meriem-Hind Ben-Mahdi
Journal:  Vet World       Date:  2018-04-12

9.  The occurrence of CTX-M-25-producing Enterobacteriaceae in day-old broiler chicks in Japan.

Authors:  Montira Yossapol; Michiyo Sugiyama; Tetsuo Asai
Journal:  J Vet Med Sci       Date:  2017-08-07       Impact factor: 1.267

10.  Phylogenetic and genomic diversity of human bacteremic Escherichia coli strains.

Authors:  Françoise Jaureguy; Luce Landraud; Virginie Passet; Laure Diancourt; Eric Frapy; Ghislaine Guigon; Etienne Carbonnelle; Olivier Lortholary; Olivier Clermont; Erick Denamur; Bertrand Picard; Xavier Nassif; Sylvain Brisse
Journal:  BMC Genomics       Date:  2008-11-26       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.